A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma

Trial Profile

A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs X4P 001 (Primary) ; Axitinib
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors X4 Pharmaceuticals
  • Most Recent Events

    • 25 May 2017 According to an X4 Pharmaceuticals media release, full results from the Phase 1 portion of the study including the selection of the once daily oral dose used in the expansion cohort will be presented at an upcoming medical meeting.
    • 25 May 2017 According to an X4 Pharmaceuticals media release, the first patient has been dosed in the phase II portion of this trial.
    • 09 May 2016 According to an X4 Pharmaceuticals media release, the first patient has been dosed in this trial. Preliminary results from the Phase 1 portion of the study are expected in early 2017, followed by the initiation of the Phase 2 portion of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top